A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma

European Journal of Cancer

Volumn 34, Issue 11, 1998, Pages 1807-1811

  Ford, J ^a,c   Osborn, C ^b   Barton, T ^b   Bleehen, N M ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b Alkermes Europe Ltd   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Carboplatin; Glioma; Progression; RMP 7

Indexed keywords

BRADYKININ B2 RECEPTOR AGONIST; CARBOPLATIN; LOBRADIMIL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; HEADACHE; HUMAN; MALE; NAUSEA; NEUTROPENIA; OLIGODENDROGLIOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TACHYCARDIA; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRADYKININ; BRAIN NEOPLASMS; CARBOPLATIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOMA; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 0032189111     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00155-5     Document Type: Article

References (29)

1. 1. Walker M, Alexander E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 1978, 49, 333-334.
2. 2. Bleehen NM, Stenning SP. A medical research council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Br J Cancer 1991, 64, 769-774.
3. 3. Prados MD, Gutin PH, Phillips TL, et al. Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience. Int J Radiation Oncol Biol Phys 1992, 24, 593-597.
4. 4. Scharfen CO, Sneed PK, Wara WM, et al. High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 1992, 24, 583-591.
5. 5. Fine HA, Dear KB, Loeffler J. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993, 71, 2585-2597.
6. 6. Stenning SP, Freedman L, Bleehen NM. An overview of published results and from randomized studies of nitrosureas in primary high grade malignant glioma. Br J Cancer 1987, 56, 89-90.
7. 7. Davies E, Hopkins A on behalf of a Working Group of the Royal College of Physicians. Good practice in the management of adults with malignant glioma: clinical guidelines. Br J Neurosurg 1997, 11, 318-330.
8. 8. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994, 12, 2013-2021.
9. 9. Thomas DG, Darling J, Paul EA, et al. Assay of anti-cancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma. Br J Cancer 1985, 51, 525-532.
10. 10. Morgan D, Freshney RI, Darling JL, Thomas DGT, Celik F. Assay of anti-cancer drugs in tissue culture: cell cultures of biopsies from human astrocytoma. Br J Cancer 1983, 47, 205-214.
11. 11. Dodion P, Sanders C, Georges P, Kenis Y. In vitro chemosensitivity of brain tumours to cisplatin and its analogues, iproplatin and carboplatin. In Cancer Chemotherapy and Pharmacology. Berlin, Springer, 1988, 80-82.
12. 12. Yung WKA, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 1991, 9, 860-864.
13. 13. Blasberg P, Groothuis DR. Chemotherapy of brain tumours: physiological and pharmacokinetic considerations. Semin Oncol 1986, 13, 70-82.
14. 14. Betz AL. An overview of the multiple functions of the blood-brain barrier. In Frankenheim J, Brown R, eds. Bioavailability of Drugs to the Brain and the BBB, Vol 120. Rockville, MD, 1992, 54-72.
15. 15. Canetta R, Goodlow J, Smaldone L, Bragman K, Rozencweig M. Pharmacologic characteristics of carboplatin: clinical experience. In Bunn Jr PA, Canetta R, Ozols RF, Rozencweig M, eds. Carboplatin (JM-8) Current Perspectives and Future Directions. Philadelphia, WB Saunders, 1990, 19-37.
16. 16. Sanovich E, Bartus RT, Friden PM, Dean RL, Le HQ, Brightman MW. Pathway across the blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res 1995, 705, 125-135.
17. 17. Inamura T, Nomura T, Bartus RT, Black KL. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg 1994, 81, 752-758.
18. 18. Bartus RT, Elliott P, Hayward N, Dean R, McEwen EL, Fisher SK. Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: evidence for a sensitive, auto-regulated, receptor mediated system. Immunopharmacology 1996, 33, 270-278.
19. 19. Ford JM, Miles KA, Hayball MP, Bleehen NM, Osborn CS, Bearcroft PW. A simplified technique for measurement of blood-brain barrier permeability using computed tomography: preliminary results of the effect of RMP-7. In Faulkner K, Carey B, Crellin A, Harrison RM, eds. Quantitative Imaging in Oncology. Proceedings of the 19th LH Gray Conference. London, British Institute of Radiology, 1996, 1-3.
20. 20. Leese PT, Grous JJ, Erb R, Graney WF. Phase I results of RMP-7 in normal volunteers. J Inv Med 1995, 43(Suppl 2), 296A (abstract).
21. 21. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7, 1748-1755.
22. 22. Rudehill A, Olsson GL, Sundquist K, Gordon E. ECG abnormalities in patients with subarachnoid haemorrhage and intracranial tumours. J Neurol Neurosurg Psychiat 1987, 50, 1375-1381.
23. 23. Koepp M, Kern A, Schmidt D. Electrocardiographic changes in patients with brain tumors. Arch Neurol 1995, 52, 152-155.
24. 24. Matsukado K, Inamura T, Nakano S, Fukui M, Bartus RT, Black KL. Enhanced uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 1996, 39, 125-134.
25. 25. Inoue T, Fukui M, Nishio S, Kitamura K, Nagara H. Hyperosmotic blood-brain barrier disruption in brains of rats with intracerebrally transplanted RG-C6 tumour. J Neurosurg 1987, 66, 256-263.
26. 26. Neuwelt EA, Barnett PA, Bigner DD, Frenkel E. Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc Natl Acad Sci USA 1982, 79, 4420-4423.
27. 27. Gumerlock MK, Belshe BD, Madsen R, Watts C. Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review. J Neuro Oncol 1992, 12, 33-46.
28. 28. Neuwelt EA, Howieson J, Frenkel EP, et al. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier edification in glioblastoma. Neurosurgery 1986, 19, 573-582.
29. 29. Iwadate Y, Namba H, Saegusa T, Sueyoshi K. Intra-arterial mannitol infusion in the chemotherapy for malignant brain tumours. J Neuro Oncol 1993, 15, 185-193.